氯化1-[2-(联苯基-3-基)-2-羟基乙基]-1H-咪唑-1-正离子 | 82837-65-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 中文名称: 氯化1-[2-(联苯基-3-基)-2-羟基乙基]-1H-咪唑-1-正离子
• 中文别名: 3-[[(E)-2-乙酰氨基乙烯基]硫代]-6-异丙基-7-氧代-1-氮杂双环[3.2.0]庚-2-烯-2-羧酸
• 英文名称: 3-[(E)-2-acetamidoethenyl]sulfanyl-7-oxo-6-propan-2-yl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
• CAS: 82837-65-8
• 化学式: C₁₄H₁₈N₂O₄S
• 分子量: 310.37
• InChiKey: LMCMRDZMDLAQJY-SNAWJCMRSA-N

物化性质

• 沸点：
  546.7±50.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Thiol derivative, metallo-beta-lactamase inhibitors
  申请人：——

  公开号：US20020019543A1

  公开（公告）日：2002-02-14

  Ar is optionally substituted with 1 to 3 R X groups, and where n is 0, 1, 2 or 3; and a group of formula III: 1 herein: R 4 is selected from hydrogen; and straight or branched alkyl; R 5 is selected from hydrogen; straight, branched, unsaturated or alicyclic alkyl, optionally substituted with 1 to 3 R X groups, where the alkyl group is optionally interrupted by X, where X is selected from O, S, NH and N(COCH 3 ); allyloxy and 9-fluorenylmethyloxy; and (CH 2 ) n Ar, where Ar is selected from phenyl, furanyl, thienyl, pyridyl, naphthyl, biphenyl, dibenzofuranyl, dibenzothienyl, fluorenyl and fluorenonyl, where n is 0, 1, 2 or 3, and where Ar is optionally substituted with 1 to 3 R X groups; and R X is selected from OR, CN, C(O)NH 2 , C(O)NHR, C(O)N(R) 2 , OC(O)NH 2 , OC(O)R, CHO, SO 2 NH 2 , SOR, CF 3 , C(O)R, COOR, F, Cl, Br, I, OCH 2 Ph, NHR, N(R) 2 ,, NHCOR, NHCO 2 t-Bu, NHCO 2 allyl, NH 2 , and R, where R is hydrogen, C 1 to C 15 alkyl, or aryl. The invention is further directed to a pharmaceutical composition containing the compound, as well as a method for treating bacterial infections in animals or humans, wherein the composition can be administered in combination with a &bgr;-lactam antibiotic.

  Ar 可以用 1 至 3 个 RX 群取代，其中 n 为 0、1、2 或 3；以及公式 III:1 中的一组，其中：R4 选自氢；直链或支链烷基；R5 选自氢、直链、支链、不饱和或脂环烷基，可选地取代 1 至 3 个 RX 群，其中烷基可以被 X 所打断，X 选自 O、S、NH 和 N(COCH3)；烯丙氧基和 9-芴甲氧基；以及 (CH2)nAr，其中 Ar 选自苯基、呋喃基、噻吩基、吡啶基、萘基、联苯基、二苯并呋喃基、二苯并噻吩基、芴基和芴烯基，其中 n 为 0、1、2 或 3，且 Ar 可选地取代 1 至 3 个 RX 群；而 RX 选自 OR、CN、C(O)NH2、C(O)NHR、C(O)N(R)2、OC(O)NH2、OC(O)R、CHO、SO2NH2、SOR、CF3、C(O)R、COOR、F、Cl、Br、I、OCH2Ph、NHR、N(R)2、NHCOR、NHCO2t-Bu、NHCO2allyl、NH2 和 R，其中 R 是氢、C1 至 C15 烷基或芳基。本发明还涉及一种含有该化合物的药物组合物，以及一种用于治疗动物或人体细菌感染的方法，其中该组合物可以与β-内酰胺类抗生素联合使用。
• EP1192128A4
  申请人：——

  公开号：EP1192128A4

  公开（公告）日：2003-07-02
• THIOL DERIVATIVE, METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1192128A1

  公开（公告）日：2002-04-03
• [EN] THIOL DERIVATIVE, METALLO-BETA-LACTAMASE INHIBITORS<br/>[FR] DERIVES DE THIOL SERVANT D'INHIBITEURS DES METALLO-BETA-LACTAMASES
  申请人：MERCK & CO INC

  公开号：WO2000076962A1

  公开（公告）日：2000-12-21

  Thiol derivative compounds, pharmaceutically acceptable salts, and biolabile esters thereof, useful for inhibiting metallo-β-lactamases, bacterial enzymes which confer resistance to clinically relevant ß-lactam antibiotics, characterized by general formula (I): wherein: R1 is selected from straight, branched, unsaturated or alicyclic alkyl, optionally substituted with from 1 to 3 R¿x? groups; and (CH2)nAr, where Ar is an aryl selected from the group consisting of phenyl, furanyl, thienyl, pyridyl, naphthyl, biphenyl, dibenzofuranyl, dibenzothienyl, fluorenyl and fluorenonyl, where n is 0, 1, 2 or 3, and where Ar is optionally substituted with 1 to 3 Rx groups; R?2¿ is selected from hydrogen; and a group of formula (II): wherein: R3 is selected from hydrogen; straight, branched, unsaturated or alicyclic alkyl, optionally substituted with from 1 to 3 R¿x? groups; (CH2)nAr, where Ar is an aryl selected from phenyl, furanyl, thienyl, pyridyl, naphthyl, biphenyl dibenzofuranyl, dibenzothienyl, fluorenyl and fluorenonyl, where Ar is optionally substituted with 1 to 3 Rx groups, and where n is 0, 1, 2 or 3; and a group of formula (III): wherein: R?4¿ is selected from hydrogen; and straight or branched alkyl; R5 is selected from hydrogen; straight, branched, unsaturated or alicyclic alkyl, optionally substituted with 1 to 3 R¿x? groups, where the alkyl group is optionally interrupted by X, where X is selected from O, S, NH and N(COCH3); allyloxy and 9-fluorenylmethyloxy; and (CH2)nAr, where Ar is selected from phenyl, furanyl, thienyl, pyridyl, naphthyl, biphenyl, dibenzofuranyl, dibenzothienyl, fluorenyl and fluorenonyl, where n is 0, 1, 2 or 3, and where Ar is optionally substituted with 1 to 3 Rx groups; and Rx is selected from OR, CN, C(O)NH2, C(O)NHR, C(O)N(R)2, OC(O)NH2, OC(O)R, CHO, SO2NH2, SOR, CF3, C(O)R, COOR, F, Cl, Br, I, OCH2Ph, NHR, N(R)2, NHCOR, NHCO2t-Bu, NHCO2allyl, NH2, and R, where R is hydrogen, C1 to C15 alkyl, or aryl. The invention is further directed to a pharmaceutical composition containing the compound, as well as a method for treating bacterial infections in animals or humans, wherein the composition can be administered in combination with a β-lactam antibiotic.